The first voluntary product recall in California was initiated by the vape cartridge manufacturer, The Bloom Brand, on July 25 and the second by Lowell Herb Co. concerning a batch of their pre-rolled cannabis cigarettes.
Californian cannabis users could be put at serious risk from fungal and bacterial contaminants as new regulations lack effective safety screenings, despite the state’s Quality Control Committee specifically advocating for such tests.
As tighter regulations mandate more rigorous testing, cannabis labs in California must plan and adapt to keep up with the huge influx of samples.
Mice who received a combination of CBD and chemotherapy survived nearly three times as long as the mice given the placebo, and around twice as long as the mice given CBD or chemotherapy alone.
Across four distinct strains it was observed that the flower samples taken from the upper third of the plant had a higher THC content than those at the base of the plant, and in two of the strains tested the difference was equivalent to the upper flowers being around twice as potent as the lower flowers.
CPC extracts products with nearly 100 percent purity at a 95 percent recovery rate and as such could be used to research, develop and produce cannabis-derived medicines.
The changes concern the reclassification of cannabis to make it a schedule 2 drug, allowing it to be prescribed by medical professionals and possessed lawfully by anybody with a valid medical prescription.
The accurate detection of microbial contamination is key to protecting consumer safety and, helping to reduce the environmental burden of pesticide use in the cannabis industry.